Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-02
2005-08-02
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S263370, C514S274000, C514S265100, C514S388000, C514S045000, C514S063000, C536S026700, C536S026800, C536S027140, C536S027400, C536S027600, C536S028500, C536S026230, C536S026260, C536S027130, C536S027810, C536S028200, C536S028510, C536S004100, C536S027210, C544S244000, C544S276000, C544S314000
Reexamination Certificate
active
06924271
ABSTRACT:
The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
REFERENCES:
patent: 4746651 (1988-05-01), Goodman
patent: 4880784 (1989-11-01), Robins et al.
patent: 5041426 (1991-08-01), Robins et al.
patent: 5248672 (1993-09-01), Townsend et al.
patent: 5424295 (1995-06-01), Krenitsky et al.
patent: 5492897 (1996-02-01), Krenitsky et al.
patent: 6479463 (2002-11-01), Wang et al.
patent: 6509320 (2003-01-01), Wang et al.
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 2002/0058635 (2002-05-01), Averett
patent: WO 89/05649 (1989-06-01), None
patent: WO 92/16215 (1992-10-01), None
patent: WO 94/17090 (1994-08-01), None
Purifoy et al. J. of Medical Virology Supplement, 1:139-145, 1993.
International Search Report mailed Mar. 18, 2003 for PCT/US02/38001.
Daskalov et al., “Synthesis and Properties of O6-Substituted Guanosine Derivatives,”Bull. Chem. Soc. Jpn., 54(10):3076-3083 (1981).
Goodman, “Role of Salvage and Phosphorylation in the Immunostimulatory Activity of C8-Substituted Guanine Ribonucleosides,”J. Immunol. 141(7):2394-2399 (1988).
Fathi et al., “Synthesis of 6-Substitued 2′-Deoxyguanosine Derivatives Using Trifluoroacetic Anhydride in Pyridine,”Tetrahedron Letters, 31(3):319-322 (1990).
Hall et al., Aldehyde Oxidase from Rabbit Liver: Specificity Toward Purines and Their Analogs,Archives of Biochemistry and Biophysics, 251(1):36-46 (1986).
Jones et al., “Di-and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside”,J. Med. Chem., 35(1):56-63 (1992).
Kini et al., “Synthesis and Antiviral Activity of Certain Guanosine Analogues in the Thiazolo[4,5-d]pyrimidine Ring System,”J. Med. Chem., 34(10):3006-3010 (1991).
Krasny et al., “Metabolism and Pharmacokinetics of a Double Prodrug of Ganciclovir in the Rat and Monkey,”Drug Metabolism and Disposition, 23(11):1242-1247 (1995).
Krasny, et al., “Allopurinol as an Inhibitor of the in vivo Formation of Acyclovir from Desciclovir,”Biochem. Pharm., 35(23):4339-4340 (1986).
Krenitsky, et al., “6-Deoxyacyclovir: A xanthine oxidase-activated prodrug of acyclovir,”Proc. Natl. Acad. Sci., 81:3209-3213 (1984).
Krenitsky, et al., “Xanthine Oxidase from Human Liver: Purification and Characterization,”Archives of Biochemistry and Biophysics, 247(1):108-119 (1986).
Nagahara et al., “Thiazolo[4,5-d] pyrimidine Nucleosides. The Synthesis of Certain 3-β-D-Ribofuranosylthiazolo[4,5-d]pyrimidines as Potential Immunotherapeutic Agents,”J. Med. Chem., 33(1):407-415 (1990).
Purifoy et al., “Review of Research Leading to New Anti-Hrpesvirus Agents in Clinical Development: Valaciclovir Hydrochloride (256U, the L-Valyl Ester of Acyclovir) and 882C, a Specific Agent for Varicella Zoster Virus,”Journal of Medical Virology Supplement, 1:139-145 (1993).
Reitz, et al., “Small-Molecule Immunostimulants. Synthesis and Activity of 7,8-Disubstituted Guanosines and Structurally Related Compounds,”J. Med Chem., (37):3561-3578 (1994).
Revankar et al., “Thiazolo[4,5-d]Pyrimidines. Part II. Synthesis and Anti-human Cytomegalovirus Activity in Vitro of Certain Acyclonucleosides and Acyclonucleotides Derived from the Guanine Analogue 5-Aminothiazolo[4,5-d]Pyrimindine-2,7(3H,6H)-dione,”Antiviral Chemistry&Chemotherapy, 9:53-63 (1998).
Rida et al., “Synthesis of Novel Thiazolo[4,5-d]Pyrimidine Derivatives for Antimicrobial, Anti-HIV Anticancer Investigation,”Pharmazie, 51(12):927-931 (1996).
Seela et al., “Alternating d(G-C)3and d(C-G)3Hexanucleotides Containing 7-Deaza-2′-deoxyguanosine or 8-Aza-7-deaza-2′-deoxyguanosine in Place of dG,”Nucleic Acids Res., 17(3):901-910 (1989).
Smee et al., “Broad Spectrum In Vivo Antiviral Activity of 7-Thia-8-Oxoguanoine, a Novel Immunopotentiating Agent,”Antimicrobial Agents and Chemotherapy, 33(9):1487-1492 (1989).
Smee et al., “Broad-Spectrum Activity of 8-chloro-7-deazaguanosine Against RNA Virus Infections in Mice and Rats,”Antiviral Res., 26:203-209 (1995).
Wong et al., “Photochemical Synthesis of 8-Hydroxyguanine Nucleosides,”Methods Enzymol, 234:59-65 (1994).
Averett Devron R.
Lennox Joseph R.
Rueden Erik J.
Webber Stephen E.
Anadys Pharmaceuticals, Inc.
Connolly Bove & Lodge & Hutz LLP
Khare Devesh
Pino, Esq. Mark J.
Wilson James O.
LandOfFree
3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3484704